Inevitably ambulance chasers attacking NTRP. This industry (ambulance chasing) needs to have some regulation, so that clinical trial results don't lead to this abusive greenmailing. I think that the company did a poor job of analyzing and presenting the results, but this doesn't rise to the level of misconduct.

Quote:

---

Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq: NTRP). Investors who purchased or otherwise acquired shares between January 7, 2016 and April 28, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the July 17, 2017 lead plaintiff motion deadline.

According to the Complaint, throughout the Class Period, Neurotrope made false and/or misleading statements and/or failed to disclose material adverse information about the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, the Company announced “positive top-line results” of the focal Phase 2b trials of Bryostatin-1, mentioning “improvement in patients with moderate to severe Alzheimer's disease.” The trial data allegedly negates these statements, however, as the top-line data relating to the 20-microgram dose of Bryostatin-1 did not produce statistically significant results. Neurotrope also allegedly failed to disclose statements about the efficacy of the 40-microgram dose in connection with its primary and secondary endpoints. Upon release of this news, Neurotrope shares dropped in value materially, which harmed investors according to the Complaint.

---